Drug boosts Helsinn Birex sales to €192m
SALES at Mulhuddart-based drug company Helsinn Birex have been boosted by growing Japanese demand for its headline drug.
Newly filed accounts show sales at the Swiss-owned company reached €192m in 2012, an increase of more than a fifth in just 12 months.
Helsinn Birex said 2012 was "an excellent year" where sales of its most important drug Palonosetron, an anti-nausea medicine used in the treatment of cancer, grew around the world.
The drug is produced at the Mulhuddart facility, the company's main manufacturing base in addition to a smaller Swiss plant. Mulhuddart is also home to its €13m research and development centre. Sales of Palonosetron were particularly successful in the Japanese market, where it was launched in 2010.
The company still received a government grant of €814,000 in the year – more than a 10th of the €7m it paid in corporation tax on profits of €62m.